Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction

Peter S. Choi, Jan Van Riggelen, Andrew J. Gentles, Pavan Bachireddy, Kavya Rakhra, Stacey J. Adam, Sylvia K. Plevritis, Dean W. Felsher

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction. However, after prolonged inactivation of MYC in a conditional transgenic mouse model of Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some of the tumors recur, recapitulating what is frequently observed in human tumors in response to targeted therapies. Here we report that these recurring lymphomas express either transgenic or endogenous Myc, albeit in many cases at levels below those in the original tumor, suggesting that tumors continue to be addicted to MYC. Many of the recurring lymphomas (76%) harbored mutations in the tetracycline transactivator, resulting in expression of the MYC transgene even in the presence of doxycycline. Some of the remaining recurring tumors expressed high levels of endogenous Myc, which was associated with a genomic rearrangement of the endogenous Myc locus or activation of Notch1. By gene expression profiling, we confirmed that the primary and recurring tumors have highly similar transcriptomes. Importantly, shRNA-mediated suppression of the high levels of MYC in recurring tumors elicited both suppression of proliferation and increased apoptosis, confirming that these tumors remain oncogene addicted. These results suggest that tumors induced by MYC remain addicted to overexpression of this oncogene.

Original languageEnglish (US)
Pages (from-to)17432-17437
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume108
Issue number42
DOIs
StatePublished - Oct 18 2011

Fingerprint

Oncogenes
Lymphoma
Neoplasms
Apoptosis
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Trans-Activators
Doxycycline
Cell Aging
Gene Expression Profiling
Tetracycline
Transgenes
Transcriptome
Small Interfering RNA
Transgenic Mice
Mutation

Keywords

  • T-cell acute lymphoblastic leukemia
  • Therapeutic resistance
  • Tumor recurrence

ASJC Scopus subject areas

  • General

Cite this

Choi, P. S., Van Riggelen, J., Gentles, A. J., Bachireddy, P., Rakhra, K., Adam, S. J., ... Felsher, D. W. (2011). Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proceedings of the National Academy of Sciences of the United States of America, 108(42), 17432-17437. https://doi.org/10.1073/pnas.1107303108

Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. / Choi, Peter S.; Van Riggelen, Jan; Gentles, Andrew J.; Bachireddy, Pavan; Rakhra, Kavya; Adam, Stacey J.; Plevritis, Sylvia K.; Felsher, Dean W.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, No. 42, 18.10.2011, p. 17432-17437.

Research output: Contribution to journalArticle

Choi, PS, Van Riggelen, J, Gentles, AJ, Bachireddy, P, Rakhra, K, Adam, SJ, Plevritis, SK & Felsher, DW 2011, 'Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction', Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 42, pp. 17432-17437. https://doi.org/10.1073/pnas.1107303108
Choi, Peter S. ; Van Riggelen, Jan ; Gentles, Andrew J. ; Bachireddy, Pavan ; Rakhra, Kavya ; Adam, Stacey J. ; Plevritis, Sylvia K. ; Felsher, Dean W. / Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. In: Proceedings of the National Academy of Sciences of the United States of America. 2011 ; Vol. 108, No. 42. pp. 17432-17437.
@article{42fa84c120dc49b18d9a17714fd120f6,
title = "Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction",
abstract = "The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction. However, after prolonged inactivation of MYC in a conditional transgenic mouse model of Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some of the tumors recur, recapitulating what is frequently observed in human tumors in response to targeted therapies. Here we report that these recurring lymphomas express either transgenic or endogenous Myc, albeit in many cases at levels below those in the original tumor, suggesting that tumors continue to be addicted to MYC. Many of the recurring lymphomas (76{\%}) harbored mutations in the tetracycline transactivator, resulting in expression of the MYC transgene even in the presence of doxycycline. Some of the remaining recurring tumors expressed high levels of endogenous Myc, which was associated with a genomic rearrangement of the endogenous Myc locus or activation of Notch1. By gene expression profiling, we confirmed that the primary and recurring tumors have highly similar transcriptomes. Importantly, shRNA-mediated suppression of the high levels of MYC in recurring tumors elicited both suppression of proliferation and increased apoptosis, confirming that these tumors remain oncogene addicted. These results suggest that tumors induced by MYC remain addicted to overexpression of this oncogene.",
keywords = "T-cell acute lymphoblastic leukemia, Therapeutic resistance, Tumor recurrence",
author = "Choi, {Peter S.} and {Van Riggelen}, Jan and Gentles, {Andrew J.} and Pavan Bachireddy and Kavya Rakhra and Adam, {Stacey J.} and Plevritis, {Sylvia K.} and Felsher, {Dean W.}",
year = "2011",
month = "10",
day = "18",
doi = "10.1073/pnas.1107303108",
language = "English (US)",
volume = "108",
pages = "17432--17437",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "42",

}

TY - JOUR

T1 - Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction

AU - Choi, Peter S.

AU - Van Riggelen, Jan

AU - Gentles, Andrew J.

AU - Bachireddy, Pavan

AU - Rakhra, Kavya

AU - Adam, Stacey J.

AU - Plevritis, Sylvia K.

AU - Felsher, Dean W.

PY - 2011/10/18

Y1 - 2011/10/18

N2 - The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction. However, after prolonged inactivation of MYC in a conditional transgenic mouse model of Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some of the tumors recur, recapitulating what is frequently observed in human tumors in response to targeted therapies. Here we report that these recurring lymphomas express either transgenic or endogenous Myc, albeit in many cases at levels below those in the original tumor, suggesting that tumors continue to be addicted to MYC. Many of the recurring lymphomas (76%) harbored mutations in the tetracycline transactivator, resulting in expression of the MYC transgene even in the presence of doxycycline. Some of the remaining recurring tumors expressed high levels of endogenous Myc, which was associated with a genomic rearrangement of the endogenous Myc locus or activation of Notch1. By gene expression profiling, we confirmed that the primary and recurring tumors have highly similar transcriptomes. Importantly, shRNA-mediated suppression of the high levels of MYC in recurring tumors elicited both suppression of proliferation and increased apoptosis, confirming that these tumors remain oncogene addicted. These results suggest that tumors induced by MYC remain addicted to overexpression of this oncogene.

AB - The suppression of oncogenic levels of MYC is sufficient to induce sustained tumor regression associated with proliferative arrest, differentiation, cellular senescence, and/or apoptosis, a phenomenon known as oncogene addiction. However, after prolonged inactivation of MYC in a conditional transgenic mouse model of Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some of the tumors recur, recapitulating what is frequently observed in human tumors in response to targeted therapies. Here we report that these recurring lymphomas express either transgenic or endogenous Myc, albeit in many cases at levels below those in the original tumor, suggesting that tumors continue to be addicted to MYC. Many of the recurring lymphomas (76%) harbored mutations in the tetracycline transactivator, resulting in expression of the MYC transgene even in the presence of doxycycline. Some of the remaining recurring tumors expressed high levels of endogenous Myc, which was associated with a genomic rearrangement of the endogenous Myc locus or activation of Notch1. By gene expression profiling, we confirmed that the primary and recurring tumors have highly similar transcriptomes. Importantly, shRNA-mediated suppression of the high levels of MYC in recurring tumors elicited both suppression of proliferation and increased apoptosis, confirming that these tumors remain oncogene addicted. These results suggest that tumors induced by MYC remain addicted to overexpression of this oncogene.

KW - T-cell acute lymphoblastic leukemia

KW - Therapeutic resistance

KW - Tumor recurrence

UR - http://www.scopus.com/inward/record.url?scp=80054830482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054830482&partnerID=8YFLogxK

U2 - 10.1073/pnas.1107303108

DO - 10.1073/pnas.1107303108

M3 - Article

C2 - 21969595

AN - SCOPUS:80054830482

VL - 108

SP - 17432

EP - 17437

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 42

ER -